Neogen (NEOG) Q4 2026 Earnings Call Transcript
Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed FY2027 revenue and adjusted EBITDA guidance ranges, the planned 50% R&D increase, and the $140M genomics divestiture intended to move net leverage toward 2.5x.
Market read
The call provides concrete FY2027 guidance and capital allocation details that can drive near-term repricing of earnings power and leverage risk.
What to watch
The guidance assumes a 1% negative currency impact and includes divestiture effects; if FX or divestiture timing differs, the revenue and margin path could deviate.
Background
Neogen’s Q4 2026 earnings call covers segment performance (Food Safety and Animal Safety), margin/EBITDA improvements, and a multiquarter transformation plan including a genomics divestiture.
Ticker impact
Neogen reported Q4 results and guided FY2027 revenue to $880M-$885M and adjusted EBITDA to $180M-$182M, plus a $140M genomics divestiture plan.
Moderate upside bias if investors view margin expansion and leverage reduction as credible; downside risk if organic growth and R&D payback timing disappoint.
The article discloses multiple decision-relevant datapoints: Q4 core growth, margin/EBITDA expansion, explicit FY2027 guidance ranges, and a $140M divestiture tied to a 2.5x net leverage target. However, it is a transcript-style summary and does not provide consensus or prior guidance comparisons.
Market effects
Food safety and animal health diagnostics demand signals (culture media, sanitation, rapid pathogen detection) may influence sentiment across lab testing and animal health tools.
International growth in Latin America and FX headwinds are explicitly discussed, which can affect regional revenue expectations.
Debt reduction and transformation spending are framed as global execution priorities, relevant to how investors price mid-cap healthcare tools balance sheets.
Counterpoint
Despite margin and EBITDA growth, the company flags that organic development cycles run 18 to 24 months, so near-term revenue upside may be limited versus investor expectations.
Key entities
- companyNeogen Corporation
Reported Q4 2026 results, provided FY2027 guidance, and discussed transformation actions including a genomics divestiture and higher R&D spending.
- executiveMikhael Nassif
CEO who discussed strategy pillars and the 18 to 24 month organic development cycle timing.
- executiveBryan Riggsbee
CFO who cited customer inflation pressures and uncertainty around the World screwworm outbreak path.
- executiveJoe Freels
Chief Commercial Officer who discussed food safety revenue mix and e-commerce contribution.
